La catena delle opzioni mostra i dati chiave delle opzioni azionarie di AbCellera Biologics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per AbCellera Biologics..

AbCellera Biologics (NASDAQ:ABCL) Azioni, Catena delle Opzioni

AbCellera Biologics

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

AbCellera Biologics Inc

Rivian Automotive Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) will receive $16 million in state incentives and tax breaks as the EV maker looks to expand its manufacturing unit in Illinois and build a supplier park.
What Happened: The company will receive the incentives from the local government, which includes tax breaks worth over $5 million from Illinois' REV (Reimagining Energy and Vehicles) program, according to a statement from the company on Monday.
Rivian is expected to invest $120 million to build the supplier park, which will help boost its lineup's production in the U.S. The supplier park is expected to span an area of 1.2 million square feet and will create hundreds of jobs, the company shared.
"We are excited to see this supplier park coming together so quickly. This will be a key enabler to increasing production at the plant in 2026 when we start to build R2 in addition to R1 and our commercial vans," Rivian CEO RJ Scaringe said.
Why It Matters: Rivian is gearing up for<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45205696/rivian-q1-earnings-preview-all-eyes-on-r2-launch-analyst-says-no-catalysts-in-2025"> its earnings call</a>, all set to take place on Tuesday. Analysts expect the company to share updates on the anticipated Rivian R2, which is the company's affordable 5-seater SUV.
Rivian also recently added AI expert and Coherent Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>) co-founder Aidan Gomez to its <a href="https://www.benzinga.com/25/04/44934176/rivian-taps-ai-expert-aidan-gomez-to-drive-innovation-advanced-technology-integration">board of directors</a>, in a move that could help Rivian develop newer tech for its vehicles.
Elsewhere, Scaringe shared that Rivian's <a href="https://www.benzinga.com/tech/25/04/44836493/rivians-us-centric-supply-chain-could-offer-edge-amid-trumps-auto-tariffs-says-ceo-rj-scaringe">U.S.-centric supply chain</a> could help the company grapple with U.S. President Donald Trump&#8216;s tariffs and provide the EV maker an edge over its competitors.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="207" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06070926/RIVN-MAY-6-2025-1024x207.jpg" alt="" class="wp-image-903014" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06070926/RIVN-MAY-6-2025-1024x207.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06070926/RIVN-MAY-6-2025-300x61.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06070926/RIVN-MAY-6-2025-768x155.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06070926/RIVN-MAY-6-2025-1536x310.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06070926/RIVN-MAY-6-2025.jpg 1655w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Rivian scores well on Momentum and Growth metrics, and has a satisfactory score on the Value metric. For more such insights, sign up for<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"> Benzinga Edge</a> today!
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45130912/ford-pulls-the-plug-on-tesla-like-next-generation-electrical-architecture-for-evs-and-ice-vehicles-report">Ford Pulls The Plug On Tesla-like Next Generation Electrical Architecture For EVs And ICE Vehicles: Report</a></li>
</ul>
Photo courtesy: Michael Berlfein / Shutterstock.com

News

Markets

Tech

General

COHR

RIVN

Rivian To Receive $16 Million Incentive As Plans For $120 Million Illinois Supplier Park Take Shape

WIIM

AHCO

AdaptHealth shares are trading higher after the company reported better-than-expected Q1 sales results.

ICHR

Ichor Holdings shares are trading lower after the company reported worse-than-expected Q1 financial results and issued Q2 guidance below estimates.

LSI Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYTS#NASDAQ">LYTS</a>), a leading U.S.-based manufacturer of commercial and industrial lighting and display solutions, announced the renewal of its partnership as an Official Lighting Sponsor of USA Pickleball. This extended collaboration highlights LSI's commitment to advancing America's fastest-growing sport through innovative lighting technologies that enhance visibility, safety, and the overall playing experience.

LYTS

LSI Industries Renews Partnership As Official Lighting Sponsor Of USA Pickleball

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Viatris Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>)</h3>
<ul>
<li>Dividend Yield: 5.59%</li>
<li>Piper Sandler analyst David Amsellem reiterated a Neutral rating and cut the price target from $14 to $10 on March 5, 2025. This analyst has an accuracy rate of 73%.</li>
<li>B of A Securities analyst Jason Gerberry maintained an Underperform rating and slashed the price target from $11 to $10 on Feb. 28, 2025. This analyst has an accuracy rate of 60%.</li>
<li>Recent News: On April 14, Viatris named Hemanth J. Varghese as Chief Strategy Officer.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506">VTRS news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506"><img loading="lazy" decoding="async" width="918" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050532/image-49.png" alt="" class="wp-image-902820" style="width:634px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050532/image-49.png 918w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050532/image-49-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050532/image-49-768x701.png 768w" sizes="(max-width: 918px) 100vw, 918px" /></a></figure>
<h3 class="wp-block-heading">Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</h3>
<ul>
<li>Dividend Yield: 4.95%</li>
<li>Piper Sandler analyst David Amsellem initiated coverage on the stock with an Overweight rating and a price target of $65 on April 22, 2025. This analyst has an accuracy rate of 73%.</li>
<li>UBS analyst Trung Huynh maintained a Neutral rating and slashed the price target from $60 to $54 on April 11, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Recent News: On April 24, Bristol Myers Squibb reported first-quarter 2025 revenues of $11.20 billion, beating the consensus of $10.70 billion.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506">latest BMY news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506"><img loading="lazy" decoding="async" width="907" height="843" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050614/image-50.png" alt="" class="wp-image-902821" style="width:561px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050614/image-50.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050614/image-50-300x279.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050614/image-50-768x714.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">Premier, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>)</h3>
<ul>
<li>Dividend Yield: 4.10%</li>
<li>Baird analyst Eric Coldwell maintained a Neutral rating and cut the price target from $20 to $19 on Feb. 5, 2025. This analyst has an accuracy rate of 79%.</li>
<li>Benchmark analyst Bill Sutherland downgraded the stock from Buy to Hold on Aug. 26, 2024. This analyst has an accuracy rate of 65%.</li>
<li>Recent News: The company is expected to announce quarterly earnings today.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506">latest PINC news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506"><img loading="lazy" decoding="async" width="906" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050643/image-51.png" alt="" class="wp-image-902822" style="width:579px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050643/image-51.png 906w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050643/image-51-300x279.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050643/image-51-768x714.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45192607/jim-cramer-applied-materials-is-an-excellent-company-but-likes-this-tech-stock-more">Jim Cramer Says Applied Materials Is An &#8216;Excellent&#8217; Company, But Likes This Tech Stock More</a> </li>
</ul>
Photo via Shutterstock

Dividends

Price Target

Pre-Market Outlook

Analyst Ratings

Trading Ideas

PINC

VTRS

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

JP Morgan analyst Lisa Gill maintains Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) with a Neutral and raises the price target from $180 to $190.

JP Morgan Maintains Neutral on Quest Diagnostics, Raises Price Target to $190

Marcus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCS#NYSE">MCS</a>) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.48) by 12.5 percent. This is a 42.11 percent decrease over losses of $(0.38) per share from the same period last year. The company reported quarterly sales of $148.77 million which beat the analyst consensus estimate of $139.89 million by 6.34 percent. This is a 7.38 percent increase over sales of $138.55 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Marcus Q1 EPS $(0.54) Misses $(0.48) Estimate, Sales $148.77M Beat $139.89M Estimate

Global Business Travel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBTG#NYSE">GBTG</a>) lowers FY2025 sales outlook from $2.50 billion-$2.55 billion to $2.38 billion-$2.48 billion vs $2.54 billion estimate.

Guidance

GBTG

Global Business Travel Lowers FY2025 Sales Guidance from $2.50B-$2.55B to $2.38B-$2.48B vs $2.54B Est

OnKure Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKUR#NASDAQ">OKUR</a>) reported quarterly losses of $(1.19) per share which beat the analyst consensus estimate of $(1.46) by 18.49 percent.

OKUR

OnKure Therapeutics Q1 EPS $(1.19) Beats $(1.46) Estimate

Global Business Travel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBTG#NYSE">GBTG</a>) sees Q2 sales of $615.000 million-$635.000 million vs $652.62 million analyst estimate.

Global Business Travel Sees Q2 Sales $615.000M-$635.000M vs $652.62M Est

SEDG

SolarEdge Technologies shares are trading higher after the company reported better-than-expected Q1 financial results and issued Q2 sales guidance above estimates.

Capitolis Taps Pagaya, Goldman Sachs Veteran Amol Naik As Coo To Lead Growth Push

Peabody Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTU#NYSE">BTU</a>) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $0.22 by 22.73 percent. This is a 6.9 percent decrease over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $937.00 million which missed the analyst consensus estimate of $949.80 million by 1.35 percent. This is a 4.74 percent decrease over sales of $983.60 million the same period last year.

Peabody Energy Q1 EPS $0.27 Beats $0.22 Estimate, Sales $937.00M Miss $949.80M Estimate

JELD

JELD-Wen Holding shares are trading lower. The comapny issued Q1 financial results.

TCMD

Tactile Systems Technology shares are trading lower after the company reported worse-than-expected Q1 sales results and lowered its FY25 sales guidance below estimates.

Global Business Travel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBTG#NYSE">GBTG</a>) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.08 by 100 percent. This is a 500 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $621.00 million which missed the analyst consensus estimate of $633.58 million by 1.99 percent. This is a 1.80 percent increase over sales of $610.00 million the same period last year.

Global Business Travel Q1 EPS $0.16 Beats $0.08 Estimate, Sales $621.00M Miss $633.58M Estimate

JP Morgan analyst Arun Jayaram maintains Cactus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHD#NYSE">WHD</a>) with a Neutral and lowers the price target from $54 to $52.

JP Morgan Maintains Neutral on Cactus, Lowers Price Target to $52

Viridian Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>) reported quarterly losses of $(0.87) per share which beat the analyst consensus estimate of $(1.01) by 13.86 percent. This is a 10.13 percent decrease over losses of $(0.79) per share from the same period last year. The company reported quarterly sales of $72.00 thousand which beat the analyst consensus estimate of $70.13 thousand by 2.67 percent. This is the same as the same period last year.

VRDN

Viridian Therapeutics Q1 EPS $(0.87) Beats $(1.01) Estimate, Sales $72.00K Beat $70.13K Estimate

Fabrinet Ordinary shares are trading lower. The company reported Q3 financial results

JP Morgan analyst Sebastiano Petti maintains Cable One (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CABO#NYSE">CABO</a>) with a Neutral and lowers the price target from $325 to $222.

CABO

JP Morgan Maintains Neutral on Cable One, Lowers Price Target to $222

Press Releases

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

AbCellera to Present at Upcoming Investor Conferences in December and January

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

AbCellera to Participate at Upcoming Investor Conferences in March

AbCellera Reports Full Year 2024 Business Results

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

AbCellera to Participate at Upcoming Investor Conferences in May and June

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

ABBV

ABCL

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Cytek Biosciences

CryoPort

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

AbCellera Biologics

AbCellera Biologics (ABCL) Opzioni

AbCellera Biologics (NASDAQ:ABCL) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO